Results 1-10 of 10 for hpv segment:7267948

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

Mr. Damien McCallion: We secured extra resources for HPV testing from the United Kingdom and other places to try to ensure we would minimise the risk. There is still an overlap with some of the people involved in managing the backlog in the current system also involved in the HPV testing project. There is still an overlap in that some of the people that are involved in managing the backlog...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

Alan Kelly: There are two or more steps. First, the resources being put in from a HSE perspective in bringing forward HPV testing have to include similar people in some way. Are the resources being put in undertaking the more immediate task - finding capacity to deal with the issue - the same as those being put in in providing HPV testing? Is this going to affect the roll-out and timeline for...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

...for the others can vary year on year. However, they can provide approximately 45% each of total capacity. One of the challenges is that as a profession or service cytology is starting to cease as HPV testing is introduced. In simple terms, in the current model, everyone a receives cytology service. Only 10% receive a HPV testing service. In the future 100% will receive a HPV testing...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

Alan Kelly: Yes. My last question is also for the HSE. What is the intended date for the implementation of HPV testing as part of cervical check? This is a very important question and lots of people watching these proceedings want to know the answer. This is absolutely critical. We need a date. A few months ago we were told it would happen within six months. When will HPV testing begin? What is...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

...indication here. The Deputy will appreciate that it is a matter for the college itself but it has given an indication that the period involved is of that order. The Deputy also asked about the HPV project and the points he made earlier are relevant in terms of prioritisation and resources. The critical issue with regard to the HPV project is that in order to run it or to implement the...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

...the capacity was in the country. That has been debated and that decision was made many years ago. In terms of value, what we are trying to look at now, as a result of the new opportunity with HPV, is how we balance that private-public mix. We need to be careful in that it is not unique to a country as such. In other words, we have some of the capacity here in Dublin in a private...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

..., the Coombe only does about 9%. One of the issues being identified is that cytologists, the professionals who do the screening, are starting to diminish as a profession because as we move to HPV testing we need fewer of those professionals. Every country in the world is struggling with this now. We have spoken to our colleagues in Northern Ireland, Australia, New Zealand and England....

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

Mr. Damien McCallion: Going forward again, looking at this as to future tenders as we are moving to HPV testing, we will ensure that whatever quality measures are needed are put in place. We have already undertaken visits to Holland and England and have made conference calls to Australia and New Zealand and there is a meeting with Northern Ireland next week, all of whom are looking at this,...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

...in. They are getting much pressure through increased referrals from general practice due to the throughput in screening. There is a process to assess the impact. When we move to working with HPV, there will initially be a significant increase in referrals to colposcopy which will then level off and reduce over years. We need to take a full view of that as a service. It is an important...

Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)

Alan Kelly: Mr. McCallion has been most eloquent, but I think this is a huge risk. I think there is a significant overlap. I do not think there are enough resources and that will affect the roll-out of HPV testing. When it comes to the backlog, some of the women who were triaged cases may have to go back for screening sooner than others. Some women might be asked to come back because of potential...